Form 4: ADMA Biologics CFO Brad L. Tade Reports Acquisition of Restricted Stock Units and Stock Options

CFO and Treasurer of ADMA Biologics, Brad L. Tade, reports the acquisition of restricted stock units and stock options, increasing his beneficial ownership in the company.

Summary

• On July 24, 2024, Brad L. Tade, CFO and Treasurer of ADMA Biologics, reported the acquisition of 72,400 shares of common stock in the form of Restricted Stock Units (RSUs).
• These RSUs will vest in four equal installments annually, starting from the grant date, under the ADMA Biologics, Inc. 2022 Equity Compensation Plan.
• Tade also acquired 115,100 stock options with an exercise price of $13.58, vesting over four years.
• Following these transactions, Tade's total beneficial ownership includes 214,433 shares of common stock and 115,100 stock options.
• The report was filed on July 26, 2024.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing indicating standard equity compensation practices. It doesn't inherently suggest positive or negative sentiment, but rather reflects ongoing management incentives.

Positives

• The acquisition of RSUs and stock options aligns the CFO's interests with the long-term performance of ADMA Biologics.
• The vesting schedules of the RSUs and stock options encourage continued service and commitment from the CFO.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain key executives, aligning their interests with shareholder value.

Comparison to Industry Standards

• Granting RSUs and stock options to key executives is a standard practice among publicly traded biotechnology companies.
• Vesting schedules of four years are also typical to ensure long-term commitment.
• Comparable companies like Grifols and CSL Behring also utilize equity compensation plans for their executives.

Stakeholder Impact

• The equity grants could potentially dilute existing shareholders, but also incentivize management to improve company performance.

Key Dates